The concurrent use of two compounds exhibited a synergistic inhibitory impact on the viability and proliferation of four types of breast cancer cells, namely triple negative (MDA-MB-231), estrogen receptor-positive (T-47D and MCF-7), and human epidermal growth factor. The gene discussed is ESR1; the disease is breast cancer.